A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
Nivolumab and Multi-fraction Stereotactic Radiosurgery (Non-Surgical Radiation Therapy) in Treating Participants With Meningioma
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAS2352
U.S. Govt. ID: NCT03604978
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This trial studies the side effects and best dose of nivolumab when given together with radiosurgery and to see how well they work with or without ipilimumab in treating participants with grade II-III meningioma that has come back. Nivolumab and ipilimumab (two different types of immunotherapy drugs), may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a type of non-surgical radiation therapy. It is not yet known whether giving nivolumab and multi-fraction stereotactic radiosurgery with or without ipilimumab may work better in treating participants with grade II-III meningioma.
This study is closed
Aya Haggiagi, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have WHO grade II-III meningioma which has relapsed after prior radiation therapy with radiologically progressive or recu Yes No
Have you had external beam radiation or radiosurgery, or combination of both? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator